drugset / Trial / NCT06760156
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
Phase 2
Recruiting
28 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Incyte Corporation · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the safety and efficacy of tafasitamab and lenalidomide in participants with Large B Cell Lymphoma (LBCL) after axicabtagene ciloleucel (axi-cel) treatment. Participants will be asked to spend about 12 months in this study.
Timeline
- Start
- 2025-03-19
- Primary completion
- 2027-01
- Completion
- 2028-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |
| Subject | Tafasitamab | Monoclonal antibody | 12 mg/kg | Intravenous |